| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We performed gene analysis in the 500 cases with head and neck cancer to identify mutaion and expression that could be the marker of treatment strategies and treatment targets for head and neck cancer.
An important prognostic factor other than TNM classification is the presence or absence of human papillomavirus (HPV) infection. In general, cancer becomes more malignant as the differentiation progresses, and the prognosis is also worsened in correlation with it. We focused on the progress of epithelial-to-mesenchymal transition as the degree of differentiation declined and the prognosis of cases in which expression of epithelial and mesenchymal markers was examined in each group.The prognosis of patients who have heterogeneity in EMT marker expression were poor. Intra-tumor heterogeneity is low in the surgical samples with HPV positive.
|
